


25 YEARS OF GIVING DOGS MORE LIFE TO LOVE

vetmedin®

MORE LIFE TO LOVE

- For over two decades, Boehringer Ingelheim has supported landmark canine cardiology studies
- Results have demonstrated the efficacy of VETMEDIN® in improving survival time and quality of life (QoL) in dogs with preclinical and clinical heart disease



Footnotes: *The composite primary endpoint was defined as the onset of left-sided CHF, cardiac-related death or euthanasia; dogs in the VETMEDIN® group were significantly less likely to reach this endpoint. Median time to composite primary endpoint was 1,228 days in the VETMEDIN® group and 766 days in the placebo group (P=0.0038). †10% more life without CHF was calculated based on an estimated lifespan for all small- to medium-sized dogs being 12.5 years. 15 months is equal to 1.25 years, which is 10% of 12.5 years.

References: 1. Lombard CW, Jöns O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. *J Am Anim Hosp Assoc.* 2006;42:249–261. 2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST Study. *J Vet Intern Med.* 2008;22:1124–1135. 3. Häggström J, Boswood A, O’Grady M, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST Study. *J Vet Intern Med.* 2013;27:1441–1451. 4. Summerfield NJ, Boswood A, O’Grady MR, et al. Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study). *J Vet Intern Med.* 2012;26:1337–1349. 5. Boswood A, Häggström J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC Study—a randomized clinical trial. *J Vet Intern Med.* 2016;30:1765–1779. 6. Boswood A, Gordon SG, Häggström J, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving pimobendan or placebo: the EPIC Study. *J Vet Intern Med.* 2018;32(1):72–85. 7. Boswood A, Gordon SG, Häggström J, et al. Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: the EPIC Study. *J Vet Intern Med.* 2020 May;34(3):1108–1118. 8. Keene BW, Atkins CE, Bonagura JD, et al. ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs. *J Vet Intern Med.* 2019;33:1127–1140. 9. Wess G, Kresken JG, Wendt R, et al. Efficacy of adding ramipril (Vasotop) to combination of furosemide (Lasix) and pimobendan (Vetmedin) in dogs with mitral valve degeneration: the VALVE Trial. *J Vet Intern Med.* 2020;34:2232–2241. 10. Wilshaw J, Rosenthal SL, Wess G, et al. Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease. *J Vet Intern Med.* 2021;35:755–770.